Emerging drugs for hepatitis C

Background: Chronic hepatitis C virus (HCV) infection remains a global health threat with approximately 200 million carriers worldwide. Current treatment consists of the use of peginterferon (pegIFN)/ribavirin (RBV) for 24 or 48 weeks depending on HCV genotype. Serious side effects and the fact that...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Expert opinion on emerging drugs 2008-03, Vol.13 (1), p.1-19
Hauptverfasser:	Soriano, Vincent, Madejon, Antonio, Vispo, Eugenia, Labarga, Pablo, Garcia-Samaniego, Javier, Martin-Carbonero, Luz, Sheldon, Julie, Bottecchia, Marcelle, Tuma, Paula, Barreiro, Pablo
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antiviral Agents - pharmacology Antiviral Agents - therapeutic use antiviral therapy boceprevir Drugs, Investigational - pharmacology Drugs, Investigational - therapeutic use Hepacivirus - drug effects Hepacivirus - physiology hepatitis C Hepatitis C - drug therapy Hepatitis C - epidemiology Hepatitis C - virology Hepatitis C virus Humans polymerase inhibitors protease inhibitors Randomized Controlled Trials as Topic - trends STAT-C telaprevir
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!